Homozygous familial hypercholesterolaemia: will new LDL-C-lowering drugs replace lipoprotein apheresis?
European Journal of Preventive Cardiology · 09.05.2026
DOI: 10.1093/eurjpc/zwag262 ↗Kurz gefasst
Editorial in der Zeitschrift European Journal of Preventive Cardiology, online erschienen am 09.05.2026. Verfasst von Angela Pirillo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for the Study of Atherosclerosis, E. Bassini Hospital, Cinisello Balsamo, Milan, Italy. Die Arbeit nennt 10 Literaturangaben. Gefördert von: Amarin, Amgen, Astrazeneca.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Center for the Study of Atherosclerosis, E. Bassini Hospital, Cinisello Balsamo, Milan, Italy.
- Center for the Study of Atherosclerosis, IRCCS MultiMedica, Via Milanese 300, 20099 Sesto S. Giovanni, Milan, Italy.
- Department of Pharmacological and Biomolecular Sciences, University of Milan, Via Balzaretti, 9, 20133 Milan, Italy.
ORCID-Profile: Angela Pirillo, Alberico L Catapano
Förderung
- Amarin
- Amgen
- Astrazeneca
- Chiesi
- Daiichi Sankyo
- Eli Lilly
- Esperion
- Ionis Pharmaceutical
Zitieren
APA
Pirillo, A., & Catapano, A. L. (2026). Homozygous familial hypercholesterolaemia: will new LDL-C-lowering drugs replace lipoprotein apheresis?. European Journal of Preventive Cardiology. https://doi.org/10.1093/eurjpc/zwag262
Vancouver
Pirillo A, Catapano AL. Homozygous familial hypercholesterolaemia: will new LDL-C-lowering drugs replace lipoprotein apheresis?. European Journal of Preventive Cardiology. 2026. doi:10.1093/eurjpc/zwag262
BibTeX
@article{Pirillo2026,
author = {Pirillo, Angela and Catapano, Alberico L},
title = {Homozygous familial hypercholesterolaemia: will new LDL-C-lowering drugs replace lipoprotein apheresis?},
journal = {European Journal of Preventive Cardiology},
year = {2026},
doi = {10.1093/eurjpc/zwag262}
}
EUVIMED